# A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

> **NCT07154745** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 35 (estimated)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** Pozelimab
- **DRUG:** Cemdisiran

## Key facts

- **NCT ID:** NCT07154745
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2030-01-06
- **Final completion:** 2031-11-22
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154745, "A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07154745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*